Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS) represents a huge clinical challenge. We previously demonstrated that serum metabolomics could distinguish RRMS from SPMS with high diagnostic accuracy. As differing sample-handling protocols can affect the blood metabolite profile, it is vital to understand which factors may influence the accuracy of this metabolomics-based test in a clinical setting. Herein, we aim to further validate the high accuracy of this metabolomics test and to determine if this is maintained in a 'real-life' clinical environment. Blood from 31 RRMS and 28 SPMS patients was subjected to different sample-handling protocols representing variations encountered in clinics. The effect of freeze-thaw cycles (0 or 1) and time to erythrocyte removal (30, 120, or 240 min) on the accuracy of the test was investigated. For test development, samples from the optimised protocol (30 min standing time, 0 freeze-thaw) were used, resulting in high diagnostic accuracy (mean ± SD, 91.0 ± 3.0%). This test remained able to discriminate RRMS and SPMS samples that had experienced additional freeze-thaw, and increased standing times of 120 and 240 min with accuracies ranging from 85.5 to 88.0%, because the top discriminatory metabolite biomarkers from the optimised protocol remained discriminatory between RRMS and SPMS despite these sample-handling variations. In conclusion, while strict sample-handling is essential for the development of metabolomics-based blood tests, the results confirmed that the RRMS vs. SPMS test is resistant to sample-handling variations and can distinguish these two MS stages in the clinics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381627 | PMC |
| http://dx.doi.org/10.1038/s41598-020-69119-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery and early validation of serum protein signatures in untreated multiple sclerosis patients: identification of candidate biomarkers for diagnosis and stratification.
Front Immunol
September 2025
Neuroimmunology and Neuroinflammation Group, Biomedical Research Institute of Málaga-IBIMA Plataforma Bionand, Hospital Regional Universitario de Málaga, Málaga, Spain.
Background: Despite progress in serum biomarker research, reliable tools for early diagnosis and patient stratification in multiple sclerosis (MS) remain limited. This study uses proteomic profiling in untreated MS patients to identify early disease-associated biomarkers.
Methods: We conducted an unbiased proteomic screen to capture broad serum protein expression profiles in a well-characterized discovery sample: 7 relapsing remitting MS (RRMS), 7 secondary progressive MS (SPMS), 4 with primary progressive MS (PPMS) alongside 6 healthy controls (HC).
Persistent progression independent of relapse activity in multiple sclerosis.
Brain Commun
August 2025
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.
Patients with relapsing-remitting multiple sclerosis (RRMS) may experience disability progression independent of relapse activity (PIRA), which can be an early sign of secondary progressive MS (SPMS). We defined persistent PIRA as ongoing sustained disability over the entire available follow-up period. However, PIRA events can regress over time.
View Article and Find Full Text PDFMultiple sclerosis patients' journey delay in diagnosis and treatment: a multicenter study.
BMC Neurol
September 2025
Neurology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Objective: To determine factors that contribute to delayed diagnosis and treatment of MS patients. Additionally, the study aimed to evaluate the correlation between diagnostic and therapeutic delay and disease outcome.
Methods: The current cohort observational multicenter study was performed at neurology clinics in four cities in Egypt.
Advanced brain diffusion MRI and image texture measures have the potential to predict multi-domain functional outcomes in multiple sclerosis.
J Neurosci Methods
August 2025
Department of Radiology, University of Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, AB, Canada; Department of Clinical Neurosciences, University of Calgary, AB, Canada. Electronic address:
Background: Multiple sclerosis (MS) causes diverse functional impairments that require early accurate characterization, but pertinent methods are scarce. This study aimed to develop new imaging-driven approaches for predicting MS functions.
New Method: 19 women with MS [10 relapsing-remitting (RRMS) and 9 secondary progressive (SPMS) subtypes] and 19 matched controls were examined including 3 T imaging.
Choroid Plexus Enlargement in Multiple Sclerosis Correlates with Cortical and Phase Rim lesions on 7-T MRI and Predicts Progression Independent of Relapse Activity.
AJNR Am J Neuroradiol
August 2025
From A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA (EB, CAT, AM, VTB, EH, JAS, ECK, NT, CM); from La Sapienza University, Department of Human Neurosciences, Rome, Italy (EB), From the Medical Physics Section, Faculty of Medicin
Background And Purpose: In multiple sclerosis (MS), the choroid plexus is thought to promote and sustain the disease immunopathological inflammatory process. However, its association with cortical pathology and disease progression is still uncertain. We aim to characterize choroid plexus enlargement and evolution in MS, its relationship with imaging markers of compartmentalized inflammation and clinical outcome.
View Article and Find Full Text PDF